- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03652142
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Predictive Biomarkers For Response To Nivolumab In Head and Neck Squamous Cell Carcinoma
Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
HNSCC whose disease has progressed within 6 months after platinum-based chemotherapy. The development of predictive biomarkers is needed to optimize patient benefit, minimize risk of toxicities and guide combination strategies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Carcinoma (HNSCC) whose disease has progressed within 6 months after platinum-based chemotherapy. The development of predictive biomarkers is needed to optimize patient benefit, minimize risk of toxicities and guide combination strategies. The greatest focus has been on tumor-cell programmed death Ligand 1 (PD-L1) expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. PD-L1 expression can be transient, and intrapatient and even intratumor heterogeneity in PD- L1 tumor expression can exist. Therefore, tumor sampling at one timepoint might not accurately reflect the state of PD1 axis in a patient. Another important aspect is that PD-L1 immunohistochemistry alone does not take into account factors that could impede the anti-PD1 therapy response such as whether or not active immune cell engagement of the PD1 axis occurs in the tumor microenvironment or other concurrent immune suppressive pathways are present.
Assessment of biomarkers at baseline may not predict benefit from immunotherapy. In a phase II study of ipilimumab in patients with metastatic melanoma baseline tumor infiltrating lymphocyte status was not associated with clinical activity. However, increase in tumor infiltrating lymphocyte density in tumor biopsy samples collected after the second dose of ipilimumab was associated with significantly greater clinical activity with ipilimumab compared to samples without increase in lymphocyte density. For a better understanding of the mechanisms of resistance to nivolumab in HNSCC, the investigators propose to study a cohort of longitudinal HNSCC samples from recurrent/metastatic HNSCC patients treated with nivolumab and identify biomarkers of response and resistance. The investigators will specifically focus on modulation of immune phenotype (ImmR) following two cycles of nivolumab as surrogate biomarker for response to nivolumab.
The primary endpoint will be the change in the percentage of immune cells that is caused by nivolumab treatment. Secondary endpoint will be safety of performing a biopsy after second nivolumab dose. Translational correlates will be tested in tumour tissue, plasma and germline DNA.
Investigator assessment of best overall response (BOR), determined between the date of first dose and the last tumor assessment (TA), will be image-based and scored using the RECIST 1.1. criteria. BOR will be defined as categorical variable with 3 levels { Benefit (complete response (CR), partial response (PR), stable disease (SD) lasting 6 months from the first nivolumab dose), no benefit (PD, progressive disease or SD lasting less than 6 months from the first nivolumab dose), and unknown} Longitudinal tissue biopsies will be collected from HNSCC patients treated with nivolumab . Biopsies will be taken at baseline, 24-72 hours after the second cycle of nivolumab and at progression.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: ELENI PAPASTAMATIOU
- Phone Number: +302105831256
- Email: lenagpa@yahoo.com
Study Locations
-
-
Chaidari
-
Athens, Chaidari, Greece
- Recruiting
- Attikon Hospital
-
Contact:
- AMANDA PSYRRI, MD
- Phone Number: +2105831664
- Email: psyrri237@yahool.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed written informed consent before any trial-related procedure is undertaken
- Male or female subjects aged ≥18 years
- Availability of a formalin-fixed, paraffin-embedded tissue sample (FFPE) containing tumor
Exclusion Criteria:
- no inform consent provided
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Recurrent/metastatic HNSCC
The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed. The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease. |
The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
Patient samples will be collected with appropriate written informed consent and analyzed.
The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the percentage of immune cells in post treatment compared to baseline biopsies
Time Frame: 2 weeks
|
Primary endpoint will be the change in mean percentage of immune cells that is caused by the nivolumab treatment
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of performing a biopsy after second nivolumab dose
Time Frame: 6 weeks
|
Incidence of adverse events attributable to nivolumab treatment
|
6 weeks
|
Best overall response rate (BOR) according to RECIST 1.1 criteria
Time Frame: One year
|
BOR will be defined as categorical variable with 3 levels { Benefit (complete response (CR), partial response (PR), stable disease (SD) lasting 6 months from the first nivolumab dose), no benefit (PD, progressive disease or SD lasting less than 6 months from the first nivolumab dose), and unknown}
|
One year
|
Number of participants with tolerability to the treatment.
Time Frame: From the 1st day of therapy and every week for 4 weeks maximum and 30 days after last therapy administration ]
|
NCI common toxicity criteria will be used
|
From the 1st day of therapy and every week for 4 weeks maximum and 30 days after last therapy administration ]
|
The burden of somatic non-synonymous mutations in association with BOR and survival
Time Frame: At baseline
|
Targeted gene sequencing using next generation sequencing will be performed
|
At baseline
|
The interferon-gamma gene signature in association with BOR and survival
Time Frame: At baseline
|
Nanostring gene expression profiling, multiple tumor, inflammatory- and immune related genes will be analyzed by multiplex Nanostring technology by using the nCounter PanCancer Immune Profiling 770-plex gene expression Panel
|
At baseline
|
The expression of PD-L1 in association with BOR and survival
Time Frame: At baseline and at 4 weeks
|
PD-L1 will be assessed in tumor cells and immune cells by immunohistochemistry
|
At baseline and at 4 weeks
|
The expression of human leukocyte antigens, HLA class I and HLA class II molecules in association with BOR and survival
Time Frame: At baseline
|
It will be assessed at RNA and protein level
|
At baseline
|
The presence of adaptive immunity cell populations
Time Frame: At baseline and at 4 weeks
|
The assessment will be performed using multiplex imaging
|
At baseline and at 4 weeks
|
The expression of PD-L2 in association with BOR and survival
Time Frame: At baseline and at 4 weeks
|
PD-L2 will be assessed in tumor cells and immune cells by immunohistochemistry
|
At baseline and at 4 weeks
|
PD-L1 expression in circulating tumor cells (CTCs) in association with BOR and survival
Time Frame: At baseline and at 4 weeks
|
The assessment will be performed with Parsotrix system
|
At baseline and at 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: AMANDA PSYRRI, MD, ATTIKON HOSPITAL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- CA209-8EN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on DNA Damage
-
Bispebjerg HospitalSygehus LillebaeltActive, not recruitingDNA Damage | Ultraviolet Rays; Injury | DNA Adduct Formation | DNA Damage, Radiation InducedDenmark
-
University of ZagrebUniversity of Split, School of MedicineRecruiting
-
University of Split, School of MedicineRecruiting
-
Tahitian Noni International, Inc.University of Illinois at ChicagoCompletedDNA DamageUnited States
-
Tufts UniversityBASFCompleted
-
Muğla Sıtkı Koçman UniversityCompleted
-
Zeynep Kamil Maternity and Pediatric Research and...Not yet recruitingDNA Damage | Granulosa Cells
-
Ricard MarcosFinnish Institute of Occupational HealthRecruitingOccupational Exposure | Genotoxicity | Damage DnaFinland, Spain
-
University of South FloridaCompletedDNA Damage | Other Complications Associated With Artificial FertilizationUnited States
-
McMaster UniversityNot yet recruitingOxidative Stress | Radiation Exposure | DNA Damage, Radiation Induced
Clinical Trials on Biomarker Research
-
M.D. Anderson Cancer CenterNational Center for Research Resources (NCRR)UnknownAdvanced CancersUnited States
-
Corporacion Parc TauliUnknown
-
University Hospital, GenevaUnknownMalnutrition | Paracetamol Toxicity | HepatotoxicitySwitzerland
-
Institut de Recherches Cliniques de MontrealCompleted
-
Wake Forest University Health SciencesSusanne Marcus Collins Foundation, Inc.Not yet recruitingDepression | Stress | Insomnia | Anxiety | Health Personnel | Job PerformanceUnited States
-
EusaPharma (UK) LimitedUniversity of Sheffield (ScHARR); KMC Health Care; Castleman Disease Collaborative...Not yet recruitingIdiopathic Multicentric Castleman's Disease
-
Necmettin Erbakan UniversityRecruitingRetinopathy of Prematurity | NewbornTurkey
-
Wake Forest University Health SciencesMemory Counseling Program general fund; Heidi Munger-Clary, MD; Hossam Shaltout... and other collaboratorsRecruiting
-
Mayo ClinicCompletedBreast Neoplasm Female | Ultrasound Therapy; ComplicationsUnited States
-
Ankara City Hospital BilkentCompleted